Metformin-pretreated synovial mesenchymal stem cell-derived exosomes alleviate osteoarthritis via the miR-1208/METTL3/NLRP3 axis - PubMed
5 days ago
- #exosomes
- #metformin
- #osteoarthritis
- Metformin-pretreated synovial mesenchymal stem cell-derived exosomes (M-EVs) alleviate osteoarthritis (OA) via the miR-1208/METTL3/NLRP3 axis.
- Clinical data showed OA patients on long-term metformin therapy had less severe joint damage.
- M-EVs enriched in miR-1208 inhibit METTL3 expression and reduce m6A modification levels of NLRP3, suppressing NLRP3 inflammasome activation.
- M-EVs promote chondrocyte proliferation, reduce apoptosis, improve ECM metabolism, and slow OA progression in animal models.
- The therapeutic effect of M-EVs is dependent on the NLRP3 pathway.
- M-EVs offer a promising acellular therapeutic strategy for OA treatment.